For the year ending 2025-12-31, FATE has $318,937K in assets. $46,628K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 46,628 | |||
| Accounts receivable | 916 | |||
| Short-term investments | 157,029 | |||
| Prepaid expenses and other current assets | 4,131 | |||
| Total current assets | 208,704 | |||
| Long-term investments | 1,472 | |||
| Property and equipment, gross | 93,148 | |||
| Less accumulated depreciation and amortization | 36,223 | |||
| Property and equipment, net | 56,925 | |||
| Operating lease right-of-use assets | 41,609 | |||
| Restricted cash | 10,227 | |||
| Other assets | 0 | |||
| Total assets | 318,937 | |||
| Accounts payable | 2,656 | |||
| Accrued expenses | 20,024 | |||
| Cirm award liability, current portion | 8,448 | |||
| Deferred revenue | 381 | |||
| Operating lease liabilities, current portion | 4,562 | |||
| Total current liabilities | 36,071 | |||
| Cirm award liability, net of current portion | 2,112 | |||
| Operating lease liabilities, net of current portion | 73,287 | |||
| Stock price appreciation milestones | 283 | |||
| Preferred stock, 0.001 par value authorized shares - 5,000,000 class a convertible preferred shares issued and outstanding - 2,755,086 at december 31, 2025 and december 31, 2024 | 3 | |||
| Common stock, 0.001 par value authorized shares - 350,000,000 at december 31, 2025 and 250,0000,000 at december 31, 2024 issued and outstanding - 115,359,735 at december 31, 2025 and 113,928,279 at december 31, 2024 | 115 | |||
| Additional paid-in capital | 1,741,259 | |||
| Accumulated other comprehensive income | 116 | |||
| Accumulated deficit | -1,534,309 | |||
| Total stockholders equity | 207,184 | |||
| Total liabilities and stockholders equity | 318,937 | |||
FATE THERAPEUTICS INC (FATE)
FATE THERAPEUTICS INC (FATE)